31575-75-4

Usage

Uses

Used in Pharmaceutical Industry:
2-BENZYLOXYBROMOBENZENE is used as a key intermediate in the synthesis of different inhibitors for pharmaceutical applications. Its unique structure allows for the development of compounds that can modulate biological pathways and target specific enzymes or receptors, leading to the creation of potential therapeutic agents.
Used in Chemical Synthesis:
In the chemical synthesis industry, 2-BENZYLOXYBROMOBENZENE serves as a valuable building block for the preparation of a wide range of organic compounds. Its reactivity and functional groups enable the formation of various derivatives, which can be further utilized in the synthesis of complex molecules for different applications.
Used in Research and Development:
2-BENZYLOXYBROMOBENZENE is also used in research and development settings to explore its potential applications and properties. Scientists and researchers can use 2-BENZYLOXYBROMOBENZENE to investigate its reactivity, stability, and interactions with other molecules, leading to the discovery of new chemical reactions and applications.
Overall, 2-BENZYLOXYBROMOBENZENE is a versatile and valuable compound with applications in various industries, including pharmaceuticals, chemical synthesis, and research and development. Its unique structure and properties make it an essential component in the development of new compounds and the advancement of scientific knowledge.

InChI:InChI=1/C13H11BrO/c14-12-8-4-5-9-13(12)15-10-11-6-2-1-3-7-11/h1-9H,10H2

Upstream product

• 95-56-7 2-hydroxybromobenzene 
• 100-39-0 benzyl bromide 
• 583-55-1 1-Bromo-2-iodobenzene 
• 100-51-6 benzyl alcohol 
• 1072-85-1 o-fluorobromobenzene 
• 584-08-7 potassium carbonate 
• 108-95-2 phenol 
• 100-44-7 benzyl chloride 

Downstream Products

• 64323-19-9 1,5-Bis-(2-benzyloxy-phenyl)-1,5-bis-(2-methoxy-5-methyl-phenyl)-pentane-1,5-diol 
• 151039-03-1 2-(2-benzyloxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 126503-51-3 1-C-(2-benzyloxyphenyl)-3,4,6-tri-O-(tert-butyldimethylsilyl)-D-glucal 
• 252554-76-0 2-(diethoxyphosphoryl)phenyloxymethylbenzene 
• 264906-63-0 3β-(2-Benzyloxyphenyl)-5α-cholestan-3α-ol 
• 190661-29-1 2-benzyloxyphenylboronic acid 
• 86610-20-0 4-(2-hydroxyphenyl)pyridine 
• 63613-47-8 3-(2-Hydroxy-4.6-dimethoxyphenyl)-3-(o-hydroxy-phenyl)-1-(3.4-dimethoxyphenyl)-1-propanol 
• 328000-16-4 (2-(benzyloxy)phenyl)magnesium bromide 
• 89376-18-1 2-benzyloxy-phenyl-sulfonyl chloride 
• 141106-98-1 1-(benzyloxy)-2-ethynylbenzene 
• 179487-56-0 3-(2'-benzyloxyphenyl)-(E)-propenoic acid methyl ester 
• 161609-77-4 1-Benzyloxycarbonyl-4-hydroxy-4-(2-benzyloxyphenyl)-piperidine 
• 13448-92-5 α-oxo-2-(phenylmethoxy)-benzeneacetic acid, methyl 

Relevant academic research and scientific papers

Total synthesis of 7- and 8-oxygenated pyrano[3,2-a]carbazole and pyrano[2,3-a]carbazole alkaloids via boronic acid-catalyzed annulation of the pyran ring

The boronic acid-catalyzed annulation of citral opens up a short route to oxygenated cyclized monoterpenoid pyranocarbazole alkaloids. Thus, murrayamine-D is available in only three steps and 55% overall yield from the corresponding carbazole precursor.

SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors

A number of reports have recently been published describing the discovery and optimization of bromo and extraterminal inhibitors which are selective for the second bromodomain (BD2); these include our own work toward GSK046 (3) and GSK620 (5). This paper describes our approach to mitigating the genotoxicity risk of GSK046 by replacement of the acetamide functionality with a heterocyclic ring. This was followed by a template-hopping and hybridization approach, guided by structure-based drug design, to incorporate learnings from other BD2-selective series, optimize the vector for the amide region, and explore the ZA cleft, leading to the identification of potent, selective, and bioavailable compounds 28 (GSK452), 39 (GSK737), and 36 (GSK217).

Improved Synthesis of MediPhos Ligands and Their Use in the Pd-Catalyzed Enantioselective N-Allylation of Glycine Esters

A new class of chiral C2-symmetric diphosphines (MediPhos) was recently shown to give superior results in the Pd-catalyzed asymmetric N-allylation of amino acid esters. We here describe a new, improved protocol for the preparation of such ligands through bidirectional SN2-coupling of a tartrate-derived ditosylate with 6-alkyl-2-bromophenols followed by double lithiation/phosphanylation. This method gave access to a series of nine ligands with branched alkyl substituents, which were benchmarked in the enantioselective Pd-catalyzed N-allylation of tert-butyl glycinate with racemic (E)-2,8-dimethylnona-5-en-4-yl methyl carbonate (up to 95 % ee). In addition, the analogous transformation of tert-butyl glycinate with methyl (E)-nona-5-en-4-yl carbonate was optimized. The obtained allylic amines were then used in the stereoselective synthesis of the conformationally restricted proline-derived dipeptide analogs ProM-17 and ProM-21.

Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of ebola virus infection

Novel 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles were designed and synthesized as Ebola virus inhibitors. The proposed structures of the new prepared benzimidazole-piperidine hybrids were confirmed based on their spectral data and CHN analyses. The target compounds were screened in vitro for their anti-Ebola activity. Among tested molecules, compounds 26a (EC50=0.93 μM, SI = 10) and 25a (EC50=0.64 μM, SI = 20) were as potent as and more selective than Toremifene reference drug (EC50 = 0.38 μM, SI = 7) against cell line. Data suggests that the mechanism by which 25a and 26a block EBOV infection is through the inhibition of viral entry at the level of NPC1. Furthermore, a docking study revealed that several of the NPC1 amino acids that participate in binding to GP are involved in the binding of the most active compounds 25a and 26a. Finally, in silico ADME prediction indicates that 26a is an idealy drug-like candidate. Our results could enable the development of small molecule drug capable of inhibiting Ebola virus, especially at the viral entry step.

Benzo four-ring derivative as well as preparation method and application thereof in medicine

The invention relates to a benzo tetracyclic derivative as well as a preparation method and medical application thereof, and particularly relates to a benzo tetracyclic derivative shown in a formula (I) or a stereisomer and a pharmaceutically acceptable salt or a predrug thereof, a preparation method thereof, a medicine composition containing the same, and application of a compound or a composition in the field of central nerve. (The formula (I) is shown in the description.).

COMPOUNDS HAVING EXCITED STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) CHARACTER FOR USE IN TREATING AND/OR PREVENTING SUNBURN AND/OR PREVENTING U.V. DAMAGE

This disclosure relates to use of cashew nut shell liquid (CNSL) phenolics in the manufacture of molecules having ESIPT character, wherein said molecules are UVA and/or UVB absorbers, and further wherein said molecules are formulated as protectants against UVA and/or UVB radiation. The disclosure extends to use of CNSL in the manufacture of compositions including molecules having ESIPT character for treating and/or preventing sunburn and/or preventing U.V. damage.

4-(2,4-BIS(2-HYDROXYPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID DERIVATIVES AS NOVEL IRON CHELATORS

The invention relates to novel compounds of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as iron chelators, more particularly for the use in the prophylaxis and/or treatm

Bimetal complex with aryloxy ether skeleton, and preparation method and application thereof

The invention provides a bimetallic complex with an aryloxy ether skeleton, and a preparation method and application of the bimetallic complex. The bimetallic complex has a structural expression as shown in the specification. A catalytic system of the bimetallic complex shows very good catalytic activity and thermal stability when being used for catalyzing olefin homopolymerization or olefin/alphaolefin copolymerization reactions, and a polymerization product generated by catalysis has relatively high molecular weight and a high alpha-olefin insertion rate and has a very good industrial application prospect.

Formation and Activation of Zr/Hf Bis(phenolate-ether) Precatalysts

Zr and Hf complexes of bis(phenolate-ether) (“O4”) ligands feature high activity, stereoselectivity and molecular weight capability for propene polymerization at high temperature. Here we report a simplified ligand synthesis and several new examples of O4